{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T03:12:15Z","timestamp":1711422735172},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n Female orgasmic disorder (FOD) is the second most frequently reported sexual dysfunction in women. According to the Diagnostic and Statistical Manual of Mental Disorders, the term \u201cmarked distress\u201d is central to the diagnosis of FOD.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n Objectives of this study were to explore terminology used by women diagnosed with FOD to describe their associated feelings and establish a correlation between patient ratings of question 15, \u201cHow often do you feel frustrated by problems with orgasm\u201d on the Female Sexual Distress Score\/Desire Arousal Orgasm (FSDS-DAO) with clinician evaluations of FOD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Research was performed at one sexual medicine facility. Recruited participants were patients diagnosed with FOD. Fifteen women meeting inclusion\/exclusion criteria were enrolled, completed the FSDS-DAO and a structured interview to assess terminology associated with orgasm difficulties.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measure<\/jats:title>\n Patient reported terminology for characterization of FOD, validity of question 15 of FSDS-DAO.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n When asked to describe their orgasm difficulties, 60% of participants said \u201cfrustrated.\u201d Other terms included disappointed, pariah, subhuman, desperate, and concerned. Fifty-three percent (53%) claimed their inability to orgasm affected day-to-day life. In participants where FOD did not affect day-to-day life, 57% actively suppressed thoughts about inability to orgasm. Responses to question 15 of the FSDS-DAO ranged from 2\u20134 (mean 3.6) indicating participants were very frustrated.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n To diagnose FOD, clinicians assess the level of associated distress through individualized patient interviews with no standardized tool. The term \u201cdistressed\u201d is a medical construct and did not resonate with participants when describing their experience. participants used \u201cfrustrated\u201d as an emotional descriptor to their sexual experience and scored high on question 15 of the FSDS-DAO. This study demonstrates the FSDS-DAO, specifically question 15, correlates well with the clinician diagnosis of marked distress and may be an appropriate tool for evaluating treatment benefit in the FOD population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jsm.12218","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T16:35:32Z","timestamp":1371659732000},"page":"2251-2254","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of Question 15 of the FSDS-DAO with Clinician Evaluation of Female Orgasmic Disorder"],"prefix":"10.1093","volume":"10","author":[{"given":"Jodi B.","family":"Dickstein","sequence":"first","affiliation":[{"name":"Trimel Pharmaceuticals Corporation , Mississauga, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue W.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"San Diego Sexual Medicine , San Diego, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Tkachenko","sequence":"additional","affiliation":[{"name":"Trimel Pharmaceuticals Corporation , Mississauga, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Kreppner","sequence":"additional","affiliation":[{"name":"Trimel Pharmaceuticals Corporation , Mississauga, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"2024032602333183000_bb0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: Prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2024032602333183000_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/00926239308404902","article-title":"Prevalence of sexual dysfunction in women: Results of a survey study of 329 women in an outpatient gynaecological clinic","volume":"19","author":"Rosen","year":"1993","journal-title":"J Sex Marital Ther"},{"key":"2024032602333183000_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/oxfordjournals.pubmed.a024665","article-title":"Sexual dysfunction in primary medical care: Prevalence, characteristics and detection by the general practitioner","volume":"19","author":"Read","year":"1997","journal-title":"J Public Health"},{"key":"2024032602333183000_bb0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: Prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2024032602333183000_bb0030","article-title":"Diagnostic and statistical manual of mental disorders","year":"2000"},{"key":"2024032602333183000_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1743-6109.2007.00672.x","article-title":"Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"Derogatis","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602333183000_bb0040","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1743-6109.2011.02634.x","article-title":"Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women","volume":"9","author":"Davis","year":"2012","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/9\/2251\/48192764\/jsm_10_9_2251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/9\/2251\/48192764\/jsm_10_9_2251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:35:17Z","timestamp":1711420517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/9\/2251\/6940128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":7,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,1]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12218","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,9]]},"published":{"date-parts":[[2013,9,1]]}}}